ARCHIVES

Two Regorafenib Trials Demonstrate Efficacy, Improve Overall and Progression-Free Survival

This article is from The Cancer Letter archive.

Vol. 35 No. 12 | December 28, 2012

Download PDF Visit The Full Archive

Related Articles

FDA Approves Votrient For Soft Tissue Sarcomas

April 27, 2012

NCAB to Review Coding of Projects Addressing Minorites and Undeserved

February 19, 1999

In Brief: Durant To Retire From ASCO In A Year; Led Society Through Management Change

July 24, 1998

HPV-Positive Women Over 30 Should Be Retested Within Two Years

September 30, 2011

The Cancer Letter Obtains “Confidential” Documents From Duke IRB Investigation

May 14, 2010

Physician Clinical Investigator Awards

April 15, 1983